Page 2599 - Hematology_ Basic Principles and Practice ( PDFDrive )

2312.e4 Part XIII Consultative Hematology

heparin for temporary interruption of warfarin. Ann Int Med 146:184– 158. Pollack CV, Jr, Reilly PA, Eikelboom J, et al: Idarucizumab for Dabi-
187, 2007. gatran Reversal. N Engl J Med 373:511–520, 2015.
148. Douketis JD, Spyropoulos AC, Kaatz S, et al: Perioperative Bridging 159. Reilly PA, van Ryn J, Grottke O, et al: Idarucizumab, a Specific Reversal
Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med Agent for Dabigatran: Mode of Action, Pharmacokinetics and Phar-
373:823–833, 2015. macodynamics, and Safety and Efficacy in Phase 1 Subjects. Am J Med
149. Crowther MA, Douketis JD, Schnurr T, et al: Oral vitamin K lowers 129:S64–S72, 2016.
the international normalized ratio more rapidly than subcutaneous 160. Pernod G, Albaladejo P, Godier A, et al: Management of major bleeding
vitamin K in the treatment of warfarin-associated coagulopathy. A complications and emergency surgery in patients on long-term treat-
randomized, controlled trial. Ann Int Med 137:251–254, 2002. ment with direct oral anticoagulants, thrombin or factor-Xa inhibitors:
150. Holbrook A, Schulman S, Witt DM, et al: Evidence-based management Proposals of the Working Group on Perioperative Haemostasis (GIHP)
of anticoagulant therapy: Antithrombotic therapy and prevention of – March 2013. Arch Cardiovasc Dis 106:382–393, 2013.
thrombosis, 9th ed: american college of chest physicians evidence-based 161. Reiffel JA, Weitz JI, Reilly P, et al: NOAC monitoring, reversal agents,
clinical practice guidelines. Chest 141:e152S–e184S, 2012. and post-approval safety and effectiveness evaluation: A cardiac safety
151. Watson HG, Baglin T, Laidlaw SL, et al: A comparison of the efficacy research consortium think tank. Am Heart J 177:74–86, 2016.
and rate of response to oral and intravenous Vitamin K in reversal of 162. Gould MK, Garcia DA, Wren SM, et al: Prevention of VTE in nonor-
over-anticoagulation with warfarin. Br J Haematol 115:145–149, 2001. thopedic surgical patients: Antithrombotic Therapy and Prevention of
152. Leissinger CA, Blatt PM, Hoots WK, et al: Role of prothrombin Thrombosis, 9th ed: American College of Chest Physicians Evidence-
complex concentrates in reversing warfarin anticoagulation: a review Based Clinical Practice Guidelines. Chest 141:e227S–e277S, 2012.
of the literature. Am J Hematol 83:137–143, 2008. 163. McGowan KE, Makari J, Diamantouros A, et al: Reducing the hospital
153. Sarode R, Matevosyan K, Bhagat R, et al: Rapid warfarin reversal: burden of heparin-induced thrombocytopenia: impact of an avoid-
a 3-factor prothrombin complex concentrate and recombinant factor heparin program. Blood 127:1954–1959, 2016.
VIIa cocktail for intracerebral hemorrhage. J Neurosurg 116:491–497, 164. Perka C: Preoperative versus postoperative initiation of thrombopro-
2012. phylaxis following major orthopedic surgery: safety and efficacy of
154. Levy JH, Key NS, Azran MS: Novel oral anticoagulants: implications postoperative administration supported by recent trials of new oral
in the perioperative setting. Anesthesiology 113:726–745, 2010. anticoagulants. Thromb J 9:17, 2011.
155. Douketis JD: Perioperative management of antithrombotic therapy: 165. Falck-Ytter Y, Francis CW, Johanson NA, et al: Prevention of VTE in
lifting the fog. J Thromb Haemost 7:1979–1981, 2009. orthopedic surgery patients: Antithrombotic Therapy and Prevention of
156. Hankey GJ, Eikelboom JW: Dabigatran etexilate: a new oral thrombin Thrombosis, 9th ed: American College of Chest Physicians Evidence-
inhibitor. Circulation 123:1436–1450, 2011. Based Clinical Practice Guidelines. Chest 141:e278S–e325S, 2012.
157. Eikelboom JW, Quinlan DJ, van Ryn J, et al: Idarucizumab: The Anti-
dote for Reversal of Dabigatran. Circulation 132:2412–2422, 2015.